Case-control study of aspirin use and risk of pancreatic cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 7, 2014, Pages 1254-1263

  Streicher, Samantha A ^a   Yu, Herbert ^c   Lu, Lingeng ^a   Kidd, Mark S ^b   Risch, Harvey A ^a  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DOSE RESPONSE; DRUG USE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK REDUCTION; CASE CONTROL STUDY; INCIDENCE; MIDDLE AGED; ODDS RATIO; PANCREATIC NEOPLASMS;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ODDS RATIO; PANCREATIC NEOPLASMS;

EID: 84904016369     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-1284     Document Type: Article

References (42)

1. American Cancer Society. Cancer Facts & Figures 2013. Atlanta: American Cancer Society; 2013.
2. Yeo TP, Lowenfels AB.Demographics and epidemiology of pancreatic cancer. Cancer J 2012;18: 477-84.
3. Eldridge RC, Gapstur SM, Newton CC, Goodman M, Patel AV, Jacobs EJ. Jewish ethnicity and pancreatic cancer mortality in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 2011;20: 691-8.
4. Anderson KE, Johnson TW, Lazovich D, Folsom AR. Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst 2002;94: 1168-71.
5. Tan XL, Reid Lombardo KM, Bamlet WR, Oberg AL, Robinson DP, Anderson KE, et al. Aspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based casecontrol study. Cancer Prev Res 2011;4: 1835-1.
6. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-Term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011;377: 31-1.
7. Bonifazi M, Gallus S, Bosetti C, Polesel J, Serraino D, Talamini R, et al. Aspirin use and pancreatic cancer risk. Eur J Cancer Prev 2010;19: 352-4.
8. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, et al. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev 2000;9: 119-3.
9. Menezes RJ, Huber KR, Mahoney MC, Moysich KB. Regular use of aspirin and pancreatic cancer risk. BMC Public Health 2002;2: 18-4.
10. Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 2003;88: 684-88.
11. Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 2004;24: 3177-84.
12. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Low-dose aspirin in the primary prevention of cancer the women's health study: a randomized controlled trial. JAMA 2005; 294: 47-5.
13. Bradley MC, Hughes CM, Cantwell MM, Napolitano G, Murray LJ. Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case-control study. Br J Cancer 2010;102: 1415-1.
14. Jacobs EJ, Newton CC, Gapstur SM, Thun MJ. Daily aspirin use and cancer mortality in a large US cohort. J Natl Cancer Inst 2012;104: 1208-7.
15. Schernhammer ES, Kang JH, Chan AT, Michaud DS, Skinner HG, Giovannucci E, et al. A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst 2004;96: 22-8.
16. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of antiinflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000;320: 1642-6.
17. Risch HA, Yu H, Lu L, Kidd MS. ABO blood group, Helicobacter pylori seropositivity, and risk of pancreatic cancer: a case-control study. J Natl Cancer Inst 2010;102: 502-5.
18. Huxley R, Ansary-Moghaddam A, Berrington de Gonz-Alez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-Analysis of 36 studies. Br J Cancer 2005;92: 2076-83.
19. Dovizio M, Bruno A, Tacconelli S, Patrignani P. Mode of action of aspirin as a chemopreventive agent. In: Chan A, Detering E, editors. Prospects for chemoprevention of colorectal neoplasia. New York: Springer-Verlag; 2013. p. 39-65.
20. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467: 1114-7.
21. Gobbi PG, Bergonzi M, Comelli M, Villano L, Pozzoli D, Vanoli A, et al. The prognostic role of time to diagnosis and presenting symptoms in patients with pancreatic cancer. Cancer Epidemiol 2013;37: 186-90.
22. Centers for Disease Control and Prevention. Prevalence of aspirin use to prevent heart disease -Wisconsin, 1991, and Michigan, 1994. Morb Mortal Wkly Rep 1997;46: 498-02.
23. Gullo L, Tomassetti P, Migliori M, Casadei R, Marrano D. Do early symptoms of pancreatic cancer exist that can allow an earlier diagnosis? Pancreas 2001;22: 210-3.
24. Bruno A, Dovizio M, Tacconelli S, Patrignani P. Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2012;26: e1-e13.
25. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-83.
26. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12: 1063-73.
27. de Groot DJ, de Vries EG, Groen HJ, de Jong S. Non-steroidal antiinflammatory drugs to potentiate chemotherapy effects: from lab to clinic. Crit Rev Oncol Hematol 2007;61: 52-69.
28. Flower RJ. The development of COX2 inhibitors. Nat Rev Drug Discov 2003;2: 179-91.
29. Matthaei H, Dal Molin M, Maitra A. Identification and analysis of precursors to invasive pancreatic cancer. Methods Mol Biol 2013; 980: 1-2.
30. Crowell PL, Schmidt CM, Yip-Schneider MT, Savage JJ, Hertzler DA 2nd, Cummings WO. Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia. Neoplasia 2006;8: 437-5.
31. Niijima M, Yamaguchi T, Ishihara T, Hara T, Kato K, Kondo F, et al. Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductal papillary-mucinous tumors of the pancreas. Cancer 2002;94: 1565-73.
32. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999;59: 4356-62.
33. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999;59: 987-90.
34. Harris RE. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacol 2009;17: 55-67.
35. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997;9: 2254-9.
36. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006;131: 1674-82.
37. Andersohn F, Suissa S, Garbe E. Use of first-And second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 2006;113: 1950-7.
38. Trelle S, Reichenbach S,Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-Analysis. BMJ 2011;342: c7086-c97.
39. Fries S, Grosser T. The cardiovascular pharmacology of COX-2 inhibition. Hematology Am Soc Hematol Educ Program 2005;1: 445-1.
40. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol 2012;9: 259-67.
41. Risch HA, Lu L, WangJ, Zhang W, Ni Q, Gao YT, et al.ABOblood group and risk of pancreatic cancer: a study in Shanghai and meta-Analysis. Am J Epidemiol 2013;177: 1326-7.
42. Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, et al. Long-Term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006;113: 203-2.